BioLight Life Sciences Ltd (BOLT) — Cash Flow-to-Debt Ratio
BioLight Life Sciences Ltd (BOLT) has a Cash Flow-to-Debt Ratio of -2.45x as of December 2025, meaning its operating cash flow of ILA-5.49 Million could theoretically repay -2% of its total liabilities (ILA2.24 Million) in one year. Explore BioLight Life Sciences Ltd long-term investment intensity to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
BioLight Life Sciences Ltd Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for BioLight Life Sciences Ltd across 14 annual periods. Also explore BioLight Life Sciences Ltd balance sheet assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for BioLight Life Sciences Ltd (2012–2025)
Year-by-year debt coverage analysis for BioLight Life Sciences Ltd. For market capitalisation and broader financial context, see BOLT stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (ILA) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.84x | ILA-10.85 Million | ILA2.24 Million | ▼ -48.8% |
| 2024 | -3.25x | ILA-10.99 Million | ILA3.38 Million | ▼ -7.0% |
| 2023 | -3.04x | ILA-9.58 Million | ILA3.15 Million | ▼ -5.7% |
| 2022 | -2.87x | ILA-9.54 Million | ILA3.32 Million | ▲ +21.0% |
| 2021 | -3.64x | ILA-10.03 Million | ILA2.75 Million | ▼ -50.9% |
| 2020 | -2.41x | ILA-11.39 Million | ILA4.72 Million | ▼ -6.9% |
| 2019 | -2.26x | ILA-15.36 Million | ILA6.80 Million | ▼ -25.9% |
| 2018 | -1.79x | ILA-22.39 Million | ILA12.49 Million | ▼ -18.5% |
| 2017 | -1.51x | ILA-25.32 Million | ILA16.73 Million | ▼ -6.2% |
| 2016 | -1.43x | ILA-26.94 Million | ILA18.90 Million | ▲ +3.9% |
| 2015 | -1.48x | ILA-24.04 Million | ILA16.21 Million | ▲ +19.3% |
| 2014 | -1.84x | ILA-26.99 Million | ILA14.70 Million | ▲ +14.4% |
| 2013 | -2.15x | ILA-26.23 Million | ILA12.22 Million | ▲ +49.8% |
| 2012 | -4.27x | ILA-19.46 Million | ILA4.55 Million | — |